Orion's Stalevo drug passes initial Phase III study

Quotes

   

HELSINKI | Thu Jan 24, 2008 1:14pm GMT

HELSINKI Jan 24 (Reuters) - Finland's Orion (ORNBV.HE) said on Thursday its partner Novartis (NOVN.VX) had informed the drug company of a first-step positive result from the Phase III clinical study for its Parkinson's disease drug Stalevo. Some 423 patients participated in the study, Orion said in a statement. (Reporting by Agnieszka Flak; Editing by David Holmes)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.